Τόμος 27 (2009) – Τεύχος 1 – Άρθρο 35 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 27 (2009) – Issue 1– Article 35 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Νικόδημος Χατζηγεωργίου και Νικόλαος Δρακούλης

Τμήμα Φαρμακευτικής, Τομέας Φαρμακευτικής Τεχνολογίας, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα, Ελλάς

Nikodimos Chatzigeorgiou, Nikolaos Drakoulis

Dep. of Pharmaceutical Technology, Faculty of Pharmacy, National & Kapodistrian University of Athens, Athens, Hellas

2. Thiebaut F., Tsuoro T., Hamada H., Gottesman M., Pastan I., Willingham M.C.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA. 84: 7735-7738 (1987)

3. Cordon-Cardo C., O’Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86: 695-698 (1989)

4. Klimecki W.T., Futscher B.W., Grogan T.M., Dalton W.S.: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83: 2451-2458 (1994)

5. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.L., Turgeon D.K., Schmiedlin-Ren P., Brown M.B., Guo W., Rossi S.J., Benet L.Z., Watkins P.B.: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62: 248-260 (1977)

6. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., Kroemer H.K.: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104: 147-153 (1999)

7. Westphal K., Weinbrenner A., Zschiesche M., Franke G., Knoke M., Oertel R., Fritz P., von Richter O., Warzok R., Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer H.K., Siegmund W.: Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68: 345-355 (2000)

8. Fromm M.F., Kim R.B., Stein C.M., Wilkinson G.R., Roden D.M.: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99: 552-557 (1999)

9. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmöller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97: 3473-3478 (2000)

10. Hitzl M., Drescher S., van der Kuip H., Schäffeler E., Fischer J., Schwab M., Eichelbaum M., Fromm M.F.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11: 293-298

11. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., Schaeffeler E., Eichelbaum M., Brinkmann U., Roots I.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69: 169-174 (2001)

12. Ameyaw M.M., Regateiro F., Li T., Liu X., Tariq M., Mobarek A., Thornton N., Folayan G.O., Githang’a J., Indalo A., Ofori-Adjei D., Price-Evans D.A., McLeod H.L.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11: 217-221 (2001)

13. : Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358(9279): 383-384 (2001)

14. Min D.I., Lee M., Ku Y.M., Flanigan M.: Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin. Pharmacol. Ther. 68: 478-486 (2000)

15. Mancinelli L.M., Frassetto L., Floren L.C., Dressler D., Carrier S., Bekersky I., Benet L.Z., Christians U.: The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. 69: 24-31 (2001)

16. Thottassery J.V., Zambetti G.P., Arimori K., Schuetz E.G., Schuetz J.D.: p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA 94: 11037-11042 (1997)

17. Panwala C.M., Jones J.C., Viney J.L.: A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 161: 5733-5744 (1998)

18. Lee C.G., Ramachandra M., Jeang K.T., Martin M.A., Pastan I., Gottesman M.M.: Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J. 14: 516-522 (2000)

19. Furuno T., Landi M.T., Ceroni M., Martignoni E., Schaeffeler E., Eichelbaum M., Schwab M., Zanger U.: MDR1 polymorphism and Parkinson’s disease. Drug Metab. Rev. 33: 129 (2001)

20. Mrozikiewicz P.M., Seremak-Mrozikiewicz A., Semczuk A., Landt O., Breborowicz G.H., Drews K.: Int. J. Gynecol. Cancer 17: 728-731 (2007)